AdvanCell secured a $315 million Series D to advance a lead-based prostate cancer radiopharmaceutical candidate and to strengthen U.S. manufacturing for a potential Pluvicto challenger. The round highlights continued capital access for radioligand and lead-targeted modalities as commercialization pressures shift to supply chain readiness. The financing is framed as both clinical and operational, with funds earmarked to support ongoing development and to shore up production capacity in the U.S. given the constraints that can limit patient access for radiopharma therapies. AdvanCell’s emphasis on manufacturing capability reflects investor focus on scale economics—where successful clinical differentiation must be matched by reliable production and distribution. Overall, the Series D points to sustained funding appetite for radioactive payloads paired with biologics-grade manufacturing discipline.